Cytokine therapy reverses NK cell anergy in MHC-deficient tumors

Journal of Clinical Investigation

Volumn 124, Issue 11, 2014, Pages 4781-4794

  Ardolino, Michele ^a   Azimi, Camillia S ^a   Iannello, Alexandre ^a   Trevino, Troy N ^a   Horan, Lucas ^a   Zhang, Lily ^a   Deng, Weiwen ^a   Ring, Aaron M ^b,c   Fischer, Suzanne ^b,c   Garcia, K Christopher ^b,c   Raulet, David H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; ANTINEOPLASTIC AGENT; HLA ANTIGEN CLASS 1; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL TRANSFORMATION; CLONAL ANERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE THERAPY; EX VIVO STUDY; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOTHERAPY; MHC CLASS I DEFICIENT TUMOR; MOUSE; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SURVIVAL TIME; T-CELL LYMPHOMA CELL LINE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR GROWTH; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; IMMUNOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CLONAL ANERGY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-12; INTERLEUKIN-18; INTERLEUKIN-2; KILLER CELLS, NATURAL; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; TUMOR ESCAPE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908636831     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI74337     Document Type: Article

References (53)

1. Margolin K. Cytokine therapy in cancer. Expert Opin Biol Ther. 2008;8(10):1495-1505.
2. Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res. 2004; 10(18 pt 2):6342S-6346S.
3. Coughlin CM, et al. Interleukin-12 and interleukin- 18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest. 1998;101(6):1441-1452.
4. Yoshimoto T, Nagai N, Ohkusu K, Ueda H, Okamura H, Nakanishi K. LPS-stimulated SJL macrophages produce IL-12 and IL-18 that inhibit IgE production in vitro by induction of IFN-γ production from CD3intIL-2R β+ T cells. J Immunol. 1998;161(3):1483-1492.
5. Yoshimoto T, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: Synergism with IL-18 for IFN-γ production. J Immunol. 1998;161(7):3400-3407.
6. Kaufman HL, Flanagan K, Lee CS, Perretta DJ, Horig H. Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine. 2002;20(13-14):1862-1869.
7. Li Q, et al. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern. Cancer Res. 2005;65(3):1063-1070.
8. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 2012;12(4):239-252.
9. Joncker NT, Raulet DH. Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells. Immunol Rev. 2008;224:85-97.
10. Shifrin N, Raulet DH, Ardolino M. NK cell self tolerance, responsiveness and missing self recognition. Semin Immunol. 2014;26(2):138-144.
11. Raulet DH, Vance RE. Self-tolerance of natural killer cells. Nat Rev Immunol. 2006;6(7):520-531.
12. Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res. 2001;83:117-158.
13. Levin AM, et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature. 2012;484(7395):529-533.
14. Ljunggren HG, Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med. 1985;162(6):1745-1759.
15. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319(6055):675-678.
16. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001;413(6852):165-171.
17. Joncker NT, Shifrin N, Delebecque F, Raulet DH. Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. J Exp Med. 2010;207(10):2065-2072.
18. Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood. 2005;105(11):4416-4423.
19. Kim S, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436(7051):709-713.
20. Attaya M, et al. Ham-2 corrects the class I antigen- processing defect in RMA-S cells. Nature. 1992;355(6361):647-649.
21. Yang Y, et al. Major histocompatibility complex (MHC)-encoded HAM2 is necessary for antigenic peptide loading onto class I MHC molecules. J Biol Chem. 1992;267(17):11669-11672.
22. Benton G, Kleinman HK, George J, Arnaoutova I. Multiple uses of basement membrane-like matrix (BME/Matrigel) in vitro and in vivo with cancer cells. Int J Cancer. 2011;128(8):1751-1757.
23. 8+ T-cell/dendritic cell interactions in vivo. Cell Immunol. 2001;214(2):110-122.
24. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816-821.
25. Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol. 2014;32(4):347-355.
26. LaBelle JL, Truitt RL. Characterization of a murine NKT cell tumor previously described as an acute myelogenous leukemia. Leuk Lymphoma. 2002;43(8):1637-1644.
27. Bix M, Liao NS, Zijlstra M, Loring J, Jaenisch R, Raulet D. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice. Nature. 1991;349(6307):329-331.
28. Liao N, Bix M, Zijlstra M, Jaenisch R, Raulet D. MHC class I deficiency: Susceptibility to natural killer (NK) cells and impaired NK activity. Science. 1991;253(5016):199-202.
29. Wei S, et al. Control of lytic function by mitogen- Activated protein kinase/extracellular regulatory kinase 2 (ERK2) in a human natural killer cell line: identification of perforin and granzyme B mobilization by functional ERK2. J Exp Med. 1998;187(11):1753-1765.
30. Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science. 2004;306(5701):1517-1519.
31. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev. 2004;68(2):320-344.
32. Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E, Walzer T. Maturation of mouse NK cells is a 4-stage developmental program. Blood. 2009;113(22):5488-5496.
33. Joncker NT, Fernandez NC, Treiner E, Vivier E, Raulet DH. NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: The rheostat model. J Immunol. 2009;182(8):4572-4580.
34. Ghiringhelli F, Menard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev. 2006;214:229-238.
35. Hoechst B, et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology. 2009;50(3):799-807.
36. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancerexpanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol. 2009;182(1):240-249.
37. 25+ regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model. Clin Exp Immunol. 2010;159(1):93-99.
38. Srivastava MK, et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One. 2012;7(7):e40677.
39. Gill S, et al. Tate K, Ritchie DS, et al. Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood. 2012;119(24):5758-5768.
40. Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. Sustained effector function of IL-12/15/18- preactivated NK cells against established tumors. J Exp Med. 2012;209(13):2351-2365.
41. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
42. Sun JC, Lanier LL. Cutting edge: viral infection breaks NK cell tolerance to "missing self". J Immunol. 2008;181(11):7453-7457.
43. Grufman P, Karre K. Innate and adaptive immunity to tumors: IL-12 is required for optimal responses. Eur J Immunol. 2000;30(4):1088-1093.
44. Nanni P, et al. Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. Cancer Res. 1998;58(6):1225-1230.
45. Romagne F, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009;114(13):2667-2677.
46. Sola C, et al. Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci USA. 2009;106(31):12879-12884.
47. Vahlne G, et al. In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: maintained tolerance to normal cells even in the presence of IL-2. Eur J Immunol. 2010;40(3):813-823.
48. Vey N, et al. A phase I trial of the anti-inhibitory KIR monoclonal antibody IPH2101 for acute myeloid leukemia (AML) in complete remission. Blood. 2012;120(22):4317-4323.
49. Glas R, et al. Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cell-mediated responses. J Exp Med. 2000;191(1):129-138.
50. Deguine J, Breart B, Lemaitre F, Di Santo JP, Bousso P. Intravital imaging reveals distinct dynamics for natural killer and CD8(+) T cells during tumor regression. Immunity. 2010;33(4):632-644.
51. Gazit R, et al. Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat Immunol. 2006;7(5):517-523.
52. Shalem O, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343(6166):84-87.
53. Reichelt P, Schwarz C, Donzeau M. Single step protocol to purify recombinant proteins with low endotoxin contents. Protein Expr Purif. 2006;46(2):483-488.